This article is more than 5 years old. Information may no longer be current.
New class of inhibitors change treatment paradigm in ALK-positive non-small cell lung cancer
Click Here to Manage Email Alerts
The development of ALK inhibitors has resulted in a ‘phenomenal’ shift in the prognosis for patients with ALK-positive non-small cell lung cancer, which affects approximately 5% of all patients with lung cancer.
Crizotinib (Xalkori; Pfizer, EMD Serono), the first ALK inhibitor, was approved by the FDA in 2011. Since then, alectinib (Alecensa, Genentech) has replaced crizotinib as first-line therapy, although ongoing research indicates that brigatinib (Alunbrig, Takeda) and lorlatinib (PF-06463922, Pfizer) may have even greater activity in the first-line setting. Additional areas of focus include combatting resistance to the ALK inhibitors and treating brain metastases, both of which are common in most patients with ALK-positive NSCLC.
This supplement, brought to you by the publishers of HemOnc Today, highlights recent developments in ALK-positive NSCLC and features commentaries from prominent physicians about the direction of future research.
Click here to view the interactive PDF and visit Healio.com/HemOnc for recent developments in the management of ALK-positive NSCLC.
